Company Filing History:
1 out of 147 
1 out of 529 
Years Active: 2019
Title: Jungo Kakuta: Innovator in Antibody Development
Introduction
Jungo Kakuta is a notable inventor based in Kobe, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. His work has implications for therapeutic applications in human health.
Latest Patents
Kakuta holds a patent for an anti-MYL9 antibody. This invention provides an anti-Myl9 antibody or a Myl9 binding fragment that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans. The patent also describes a pharmaceutical composition that includes this antibody. A mouse anti-human/mouse Myl9 monoclonal antibody with binding affinity against Myl9 was developed, and the sequence for the complementarity determining region (CDR) of this antibody was identified. Consequently, a humanized antibody incorporating the CDR sequence in the variable region of heavy and light chains was produced.
Career Highlights
Throughout his career, Jungo Kakuta has worked with esteemed institutions, including Chiba University and Eisai R&D Management Co., Ltd. His experience in these organizations has contributed to his expertise in antibody research and development.
Collaborations
Kakuta has collaborated with notable colleagues such as Toshinori Nakayama and Motoko Kimura. Their joint efforts have further advanced the research in the field of antibodies.
Conclusion
Jungo Kakuta's innovative work in the development of the anti-MYL9 antibody showcases his significant contributions to biotechnology. His research has the potential to impact therapeutic strategies in human health.